Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Department of Psychiatry, Huashan Hospital, Fudan University, School of Medicine, No. 12 Wulumuqi Road (middle), Shanghai 200040, China.
J Affect Disord. 2024 Oct 15;363:619-625. doi: 10.1016/j.jad.2024.07.142. Epub 2024 Jul 21.
Major depressive disorder (MDD) is a serious and disabling condition characterized by abnormal mood changes. Clinical guidelines for depression treatment recommend antidepressant medications, with benzodiazepines acting as short-term synergists. However, little is currently known about the prevalence and associated clinical risk factors of benzodiazepine use among Chinese patients with MDD. This study aimed to explore the prevalence and clinical risk factors associated with benzodiazepine use in this population.
A total of 2742 patients with MDD (males/females = 816/1926, aged 14-60 years) participated in this cross-sectional observational study. General information and psychosis assessments were collected online. Depressive symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9), anxiety symptoms using the Generalized Anxiety Disorder-7 (GAD-7), and sleep problems and suicidal tendencies using the third and ninth items of the PHQ-9. Multivariable logistic regression analysis models were employed to identify factors associated with benzodiazepine use.
The prevalence of benzodiazepine use among patients with MDD was 42.9 %. Among these patients, 99.6 % used a single benzodiazepine, with oxazepam being the most frequently prescribed. Age, severity of sleep problems, depressive symptoms, and anxiety symptoms were significantly correlated with benzodiazepine use (all P < 0.001).
The cross-sectional design of this study precludes establishing causal relationships.
Our findings indicate a high prevalence of benzodiazepine use among Chinese patients with MDD. Factors such as severe depressive symptoms, anxiety symptoms, age, and sleep problems appear to be associated with benzodiazepine use. These results underscore the importance of vigilance regarding benzodiazepine use in patients with MDD.
重度抑郁症（MDD）是一种严重且致残的疾病，其特征为异常的情绪变化。抑郁症治疗的临床指南推荐使用抗抑郁药物，苯二氮䓬类药物作为短期协同药物。然而，目前对于中国 MDD 患者使用苯二氮䓬类药物的流行情况及其相关临床危险因素知之甚少。本研究旨在探讨该人群中使用苯二氮䓬类药物的流行情况及其相关临床危险因素。
共 2742 例 MDD 患者（男性/女性=816/1926，年龄 14-60 岁）参与了这项横断面观察性研究。在线收集一般信息和精神病学评估。使用患者健康问卷-9（PHQ-9）评估抑郁症状，使用广泛性焦虑症-7（GAD-7）评估焦虑症状，使用 PHQ-9 的第 3 和第 9 项评估睡眠问题和自杀倾向。采用多变量逻辑回归分析模型来确定与苯二氮䓬类药物使用相关的因素。
MDD 患者中苯二氮䓬类药物使用的患病率为 42.9%。在这些患者中，99.6%使用单一苯二氮䓬类药物，其中奥沙西泮的使用最为常见。年龄、睡眠问题严重程度、抑郁症状和焦虑症状与苯二氮䓬类药物使用显著相关（均 P<0.001）。
本研究的横断面设计限制了因果关系的确立。
我们的研究结果表明，中国 MDD 患者中苯二氮䓬类药物的使用较为普遍。严重的抑郁症状、焦虑症状、年龄和睡眠问题等因素与苯二氮䓬类药物的使用相关。这些结果强调了在 MDD 患者中警惕使用苯二氮䓬类药物的重要性。
